Optimizing sequential ADC therapy for HER2-low breast cancer
Part of Cancer, Skin clinical trials.
This trial is for people with HER2-low breast cancer who have already received two or more antibody-drug conjugates (ADCs) in a row. Researchers want to find the best order to use these targeted therapies to get the most benefit.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your breast cancer has a low level of the HER2 protein (called HER2-low, scored 1+ or 2+ with a negative FISH test).
- You have already received at least two different antibody-drug conjugates (ADC) one after the other.
- Your complete medical records (lab tests, scans, treatment history, and follow-up) are available to the study team.
- You did not have any other type of cancer at the time of your breast cancer diagnosis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a sequence of antibody-drug conjugates (ADCs) for advanced breast cancer that is hormone receptor positive and HER2 negative, after standard therapy has stopped working. It aims to find a new treatment option for people whose disease has progressed on a CDK4/6 inhibitor and endocrine therapy.
This trial tests two antibody-drug conjugates (Enhertu and Datroway) for breast cancer that is HER2-low or HER2-0. It aims to find the best treatment sequence for people whose cancer has stopped responding to prior therapy.
This study tests a new treatment combining two drugs (SSGJ-612 and an antibody-drug) for people with a certain type of advanced breast cancer (hormone receptor-positive and HER2-low or ultra-low). The goal is to see if this combination can help when endocrine therapy has stopped working.
This study tests a new drug called Trop2-ADC, either alone or combined with immunotherapy, for people with advanced triple-negative breast cancer. The goal is to see if it can shrink tumors and improve outcomes.
This trial is testing the best time to give an antibody-drug conjugate (ADC) to people with advanced breast cancer that is HER2-negative. It aims to find out if giving this treatment after first chemotherapy fails can help slow the cancer's growth.
This study tracks how well antibody-drug conjugates (ADCs) work for breast cancer that has spread. You may join if you are about to start your first or second ADC for hormone receptor-positive/HER2-negative or triple-negative breast cancer.
Hear when a new Antibody-drug Conjugates trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.